ScholarIQanswers from OpenAlex
Bristol-Myers Squibb (United States)
InstitutionResearch output, impact & collaborations
Bristol-Myers Squibb (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Bristol-Myers Squibb (United States)?
ScholarIQrecord summary
Bristol-Myers Squibb (United States) is a research organisation in New York, US. OpenAlex records 22,768 works and 4,601,003 citations for it. 6,876 researchers list it as their most recent affiliation.
How many works does Bristol-Myers Squibb (United States) have?
ScholarIQindexed works
Bristol-Myers Squibb (United States) has 22,768 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bristol-Myers Squibb (United States) have?
ScholarIQcitation count
Bristol-Myers Squibb (United States) has 4,601,003 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Bristol-Myers Squibb (United States)?
ScholarIQresearcher count
Bristol-Myers Squibb (United States) has 6,876 researchers in the ScholarIQ index.
What is the average h-index at Bristol-Myers Squibb (United States)?
ScholarIQavg h-index
Bristol-Myers Squibb (United States) has an average h-index of 39.6 in OpenAlex.
What is the ROR of Bristol-Myers Squibb (United States)?
ScholarIQror
The ROR for Bristol-Myers Squibb (United States) is on the source record.
What is the OpenAlex record for Bristol-Myers Squibb (United States)?
ScholarIQopenalex
The OpenAlex for Bristol-Myers Squibb (United States) is on the source record.
Who are the most-cited researchers behind Bristol-Myers Squibb (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Bristol-Myers Squibb (United States)?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
Functional profiling of the Saccharomyces cerevisiae genome
Guri Giaever, Angela Chu, Li Ni, Carla J. Connelly, Linda Riles, Steeve Véronneau, Sally Dow, Ankuta Lucau-Danila, Keith M. Anderson, Bruno André, Adam P. Arkin, Anna Astromoff, Mohamed El Bakkoury, Rhonda Bangham, Rocío Benito, Sophie Brachat, Stefano Campanaro, Matt Curtiss, Karen Davis, Adam M. Deutschbauer, Karl-Dieter Entian, Patrick Flaherty, Françoise Foury, David Garfinkel, Mark Gerstein, Deanna Gotte, Ulrich Güldener, Johannes H. Hegemann, Svenja Hempel, Zelek S. Herman, Daniel F. Jaramillo, Diane Kelly, Steven L. Kelly, Peter Kötter, Darlene LaBonte, David C. Lamb, Ning Lan, Hong Liang, Hong Liao, Lucy Liu, C. Luo, Marc Lussier, Rong Mao, P Ménard, Siew Loon Ooi, José Luis Revuelta, Christopher J. Roberts, Matthias Rose, Petra Ross‐Macdonald, Bart Scherens, Greg Schimmack, Brenda Shafer, Daniel Shoemaker, Sharon Sookhai-Mahadeo, Reginald Storms, Jeffrey N. Strathern, Giorgio Valle, Marleen Voet, Guido Volckaert, Ching-Yun Wang, Teresa R. Ward, Julie Wilhelmy, Elizabeth A. Winzeler, Yonghong Yang, Grace S. Yen, Elaine M. Youngman, Kexin Yu, Howard Bussey, Jef D. Boeke, M Snyder, Peter Philippsen, Ronald W. Davis, Mark Johnston
Who collaborates most closely around Bristol-Myers Squibb (United States)?
ScholarIQco-authorship network
United States
70%
France
10%
Israel
10%
India
10%
How much of the research on Bristol-Myers Squibb (United States) is open access?
ScholarIQopen access share
58%OPEN ACCESS